Bausch+Lomb Results Presentation Deck
2023 Strategic Focus ¹
1
Continue momentum
in current portfolio
Invest in categories
growing faster than
market
Expand into new
product categories
BAUSCH + LOMB
1. See Slide 1 for further information on forward-looking statements.
Strong performance targeted in key franchises: Ocuvite® + PreserVision®, Lumify®, Artelac®,
Bio True® Global Mega Brand and core vision care brands (BioTrue ONEday, Bausch + Lomb
ULTRA®, Daily SiHy)
Continued geo-expansion and line extensions anticipated in numerous key franchises
• Opportunity for market share gains across key franchises
Launch new innovations into several high-growth markets
Continued rollout of Daily SiHy, including expected launch of multi-focal in U.S.
• Strong performance targeted in implantables, following premium IOL rollout and AcuFocus acquisition
Expected approval of NOV03 (PDUFA date June 2023)
Strong balance sheet with the flexibility to pursue value enhancing bolt-on acquisitions
●
●
●
●
●
●
●
Launching premium IOL, IC-8 Apthera TM (AcuFocus acquisition), in the U.S.
Expected launch of LUMIFY® Eye Illuminations
Expected launch of enVista® Aspire TM (enVista® Extended Range Monofocal IOL)
Expected launch of 3D microscope
Expected launch of NOV03
TM
Expected launch of eye Telligence ™ platform
26View entire presentation